Amniocentesis is a procedure whereby fluid is extracted

Amniocentesis is a procedure whereby fluid is extracted from the amniotic sac. The amniotic sac is the fluid-filled structure inside the pregnant uterus within which the baby lives. Fetal cells, proteins, and fetal urine freely move within this sac.

During amniocentesis, fluid is removed by placing a long needle through the abdominal wall into this sac. Sometimes, the woman’s skin is injected first with a local anesthetic, but this is not always necessary. Occasionally, the amniocentesis needle is guided into the sac with the help of ultrasound imaging. Once the needle is in the sac, a syringe is used to withdraw the clear amber-colored amniotic fluid, resembling urine. The volume of fluid withdrawn depends upon the age of the fetus and the reason for the testing.

The fluid can then be sent for evaluation of fetal lung maturity, genetic evaluation, evidence of spina bifida (a birth defect in spinal cord development), the presence of infection, or chromosome analysis. Chromosomes are microscopic messengers that contain all of the genetic information in our cells. The amniotic fluid contains numerous free-floating fetal cells that can be grown in a laboratory. When these cells multiply and reach a certain number, their chromosomes or genes are extracted and analyzed. It takes about two weeks to perform chromosome analysis. The fluid also contains proteins, minerals and other compounds that can be tested, and may take 1 to 7 days to perform. Data obtained from amniotic fluid can help women make informed decisions regarding their pregnancies and babies.

For most patients, amniocentesis is a fairly quick and comfortable procedure. Some women experience some uterine cramping or a feeling of faintness.

Women over the age of 35 have an increased chance of carrying a baby with chromosomal abnormalities. Therefore, the current recommendation is that women who will be age 35 or older at the time of delivery consider having an amniocentesis for fetal chromosome testing. Chromosomal abnormalities in the fetus can lead to mental retardation or other birth defects as seen with Down’s syndrome. The possibility of having a baby with a chromosomal defect increases with the age of the mother. This is because of the aging of the eggs in the ovaries. The older the egg, the greater the likelihood of chromosomal abnormalities. At age 35 the chance is about 1 in 178. By age 40, the rate increases to 1 in 63. By age 48, the ratio is 1 in 8. Fetal loss as a complication of amniocentesis occurs in about 1 in 200 procedures. Therefore, for women younger than 35, the risk of complications as a result of amniocentesis outweighs the possibility that the baby has a chromosomal abnormality. After 35, the chance of carrying a baby with a chromosomal abnormality is more common than experiencing the complications associated with this procedure.

If there is a family history of chromosomal problems or history of prior fetal birth where a chromosomal problem was found, amniocentesis may be recommended. However, the exact benefit of amniocentesis in these situations is uncertain. Many chromosomal defects may not reappear in subsequent pregnancies. Amniocentesis in these women can actually put the baby at a greater risk from the procedure than the possiblility that the baby has a chromosomal abnormality.

Amniocentesis is very accurate in detecting chromosomal abnormalities and gender of the fetus. Occasionally, the fetal cells harvested by amniocentesis do not grow in culture and no chromosome data can be obtained. Additionally, the doctor occasionally is unable to extract fluid from the uterus during amniocentesis due to a variety of technical reason. In both instances, the procedure can be repeated. Amniocentesis testing for lung maturity can help the doctor make decisions regarding timing of delivery for women in premature labor, or those with diabetes or other medical conditions requiring delivery. Lung maturity testing is not perfect. In rare instances, a baby is born with apparently mature lungs but still experiences difficulty breathing.

The AFP (alpha feto protein) blood test is currently available and can be used to screen for spina bifida and Down’s syndrome. An elevated AFP blood level may indicate the possibility that the fetus has spina bifida, a defect in brain and spinal cord development. A low AFP level may indicate the potential for Down’s syndrome. When abnormal levels of AFP are found, further evaluation with ultrasound and amniocentesis can be done to look for birth defects and chromosomal abnormalities.

Amniocentesis can also help determine if there are specific genetic problems present in the fetus. Testing for Tay-Sachs disease, cystic fibrosis, sickle cell anemia, and other inherited disorders can be performed on samples of amniotic fluid. Checking the cells for specific genes can now be done on the fetal cell cultures. It is also possible to look for a specific protein in the amniotic fluid that can signal a genetic abnormality. Testing for genetic (inherited) diseases is not routinely performed, but is available.

Another common reason for performing amniocentesis is to determine if the fetal lungs are mature enough so that the baby can be safely delivered before the due date. If the fetal lungs are not mature, an attempt can be made to stop premature labor with medications. If the lung tissues are mature, it may be safe for the premature baby to be born. This test can also help in the timing of delivery when the due date is uncertain.

Occasionally, a pregnant woman may have a fever without an obvious site of infection. In these instances, an amniocentesis may be performed to determine if the cause of the mother’s fever is from an intrauterine infection, when the source of the infection is unclear.

During amniocentesis, blood can be obtained from the umbilical cord to see if the fetus is anemic. Anemic fetuses can be given blood transfusions while they are still in the uterus through a process called cordocentesis. In other instances, sterile fluid can be instilled into the sac around the fetus to allow better visualization of fetal anatomy during ultrasound examination.

The overall possibility of birth defects in any pregnancy is approximately 3%. For defects such as cleft lip, hernia, and extra fingers or toes, there are no prenatal screening tests and amniocentesis will not be of benefit. Ultrasound is the only helpful test in detecting these defects in the fetus.

For genetic testing, chromosome analysis, and evaluation of an abnormal AFP test, amniocentesis is usually performed between the 15th and the 18th week of pregnancy. Some physicians perform "early amnio" at 13 weeks or even sooner. There is a higher rate of miscarriage associated with these very early tests. However, early tests can provide information sooner which may be helpful to the parents. There is no time limit as to how late in the pregnancy amniocentesis can be performed.

If amniocentesis is performed to determine fetal lung maturity, it is often done anywhere between the 32nd and 36th week of pregnancy. In diabetic women, lung maturity testing may be done as late as the 39th week, because poorly controlled diabetes may delay fetal lung maturity.

Overall, amniocentesis is a safe procedure with the risk of fetal loss at generally less than 1%. Since there is the possibility of losing the baby from the procedure, amniocentesis should be performed only when clearly indicated. Many parents ask for the procedure to "reassure" themselves that everything is perfect. It should be emphasized that a normal amniocentesis does not guarantee that the baby will be "perfect." Many birth defects cannot be detected by amniocentesis. Besides fetal loss, other risks associated with amniocentesis include bleeding, cramping and leakage of fluid from the vagina. These problems occur in about 1% of women undergoing the procedure, and generally resolve on their own. If these symptoms arise following the procedure, the woman is often advised to stop work and remain at bed rest until the symptoms cease. Subsequent activity will be proscribed by the doctor. Occasionally, the fetus is poked with the needle during the testing, but this is generally harmless.

Amniocentesis is a relatively safe and painless procedure that can provide helpful information. The procedure can be offered to selected women after reviewing the risks and benefits involved.

√ Pregnant women over the age of 35 years are candidates for amniocentesis to detect chromosomal abnormalities in the fetus.
√ Amniocentesis can be used to determine the maturity of the lungs of the fetus or the cause of unknown fever in the mother.
√ For genetic testing, chromosome analysis, and the evaluation of an abnormal alpha feto protein test, amniocentesis is usually performed between the 15th and 18th weeks of pregnancy.
√ The risk of fetal loss from the amniocentesis procedure is less than 1%.